Amgen Inc. $AMGN Stock Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 65.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,428 shares of the medical research company’s stock after purchasing an additional 1,752 shares during the period. Fulcrum Asset Management LLP’s holdings in Amgen were worth $1,876,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Wellington Altus USA Inc. increased its position in shares of Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares during the last quarter. Quest 10 Wealth Builders Inc. raised its holdings in shares of Amgen by 220.0% during the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after buying an additional 55 shares in the last quarter. Nvwm LLC raised its holdings in shares of Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after buying an additional 66 shares in the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen in the 2nd quarter worth approximately $36,000. Finally, PFS Partners LLC lifted its position in Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after buying an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $465.23 on Wednesday. The stock’s 50-day moving average is $423.79 and its 200 day moving average is $379.39. The company has a market cap of $251.65 billion, a PE ratio of 26.99, a P/E/G ratio of 3.25 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business’s revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business posted $5.64 EPS. Sell-side analysts anticipate that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. Amgen’s dividend payout ratio (DPR) is presently 58.47%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on AMGN shares. Wells Fargo & Company upped their target price on Amgen from $430.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. lifted their price target on shares of Amgen from $350.00 to $425.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. BMO Capital Markets decreased their price target on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a research note on Monday, October 12th. Scotiabank boosted their price objective on shares of Amgen from $500.00 to $530.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 4th. Finally, Bank of America upped their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $422.76.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.